Form 4: Abeona Therapeutics CEO Vishwas Seshadri Sells $25,000 in Common Stock

Abeona Therapeutics CEO Vishwas Seshadri sold 25,000 shares of common stock on March 31, 2025, at an average price of $4.78, according to a Form 4 filing with the SEC.

Summary

• Vishwas Seshadri, CEO of Abeona Therapeutics, sold 25,000 shares of common stock on March 31, 2025.
• The sale was executed at a weighted average price of $4.78 per share.
• The transactions occurred at prices ranging from $4.71 to $4.81.
• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 18, 2024.
• Following the transaction, Seshadri directly owns 1,355,322 shares of Abeona Therapeutics.
• The filing was made with the Securities and Exchange Commission (SEC).

Sentiment

Score: 5

Explanation: The document is a neutral report of an insider stock sale. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This transaction is a routine disclosure of insider trading activity. It's common for executives to sell shares under pre-arranged trading plans to diversify their holdings or for personal financial planning.

Stakeholder Impact

• The sale of shares by the CEO could be perceived negatively by some investors, potentially leading to a slight decrease in stock price, although the sale was conducted under a pre-arranged trading plan.

Key Dates

Keywords

Abeona Therapeutics, ABEO, Vishwas Seshadri, SEC Form 4, Stock Sale, Rule 10b5-1, Insider Trading